LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,113
تعداد مقالات10,208
تعداد مشاهده مقاله40,779,970
تعداد دریافت فایل اصل مقاله8,803,885
Zheng, Zequn, Zhou, Jiaozhi, Song, Yongfei. (1403). Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis. سامانه مدیریت نشریات علمی, 49(5), 275-285. doi: 10.30476/ijms.2024.99837.3196
Zequn Zheng; Jiaozhi Zhou; Yongfei Song. "Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis". سامانه مدیریت نشریات علمی, 49, 5, 1403, 275-285. doi: 10.30476/ijms.2024.99837.3196
Zheng, Zequn, Zhou, Jiaozhi, Song, Yongfei. (1403). 'Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis', سامانه مدیریت نشریات علمی, 49(5), pp. 275-285. doi: 10.30476/ijms.2024.99837.3196
Zheng, Zequn, Zhou, Jiaozhi, Song, Yongfei. Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis. سامانه مدیریت نشریات علمی, 1403; 49(5): 275-285. doi: 10.30476/ijms.2024.99837.3196

Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis

Iranian Journal of Medical Sciences
مقاله 1، دوره 49، شماره 5، مرداد 2024، صفحه 275-285    اصل مقاله (1.75 M)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.30476/ijms.2024.99837.3196
نویسندگان
Zequn Zheng1، 2؛ Jiaozhi Zhou3؛ Yongfei Song* 1، 4
1Ningbo Institute of Innovation for Combined Medicine and Engineering, Ningbo Medical Center Lihuili Hospital, Ningbo University, No. 378 Dongqing Road, Yinzhou District, Ningbo
2Department of Cardiology, Shantou University Medical College, Shantou University, Shantou, 515000, China
3Department of Gastroenterology, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China
4School of Medicine, Ningbo University, Ningbo, 315211, Zhejiang, China
چکیده
Background: The RNA-dependent RNA polymerase (RdRp) inhibitors, molnupiravir and VV116, have the potential to maximize clinical benefits in the oral treatment of COVID-19. Subjects who consume these drugs may experience an increased incidence of adverse events. This study aimed to evaluate the safety profile of molnupiravir and VV116.
Methods: A comprehensive search of scientific and medical databases, such as PubMed Central/Medline, Embase, Web of Science, and Cochrane Library, was conducted to find relevant articles in English from January 2020 to June 2023. Any kind of adverse events reported in the study were pooled and analyzed in the drug group versus the control group. Estimates of risk effects were summarized through the random effects model using Review Manager version 5.2, and sensitivity analysis was performed by Stata 17.0 software.
Results: Fifteen studies involving 32,796 subjects were included. Eleven studies were placebo-controlled, and four were Paxlovid-controlled. Twelve studies reported adverse events for molnupiravir, and three studies described adverse events for VV116. The total odds ratio (OR) for adverse events in the RdRp inhibitor versus the placebo-controlled group was 1.01 (95% CI=0.84-1.22; I2=26%), P=0.88. The total OR for adverse events in the RdRp inhibitor versus the Paxlovid-controlled group was 0.32 (95% CI=0.16-0.65; I2=87%), P=0.002. Individual drug subgroup analysis in the placebo-controlled study showed that compared with the placebo group, a total OR for adverse events was 0.97 (95% CI, 0.85-1.10; I2=0%) in the molnupiravir group and 3.77 (95% CI=0.08-175.77; I2=85%) in the VV116 group.
Conclusion: The RdRp inhibitors molnupiravir and VV116 are safe for oral treatment of COVID-19. Further evidence is necessary that RdRp inhibitors have a higher safety profile than Paxlovid.
کلیدواژه‌ها
COVID-19؛ RNA-dependent RNA polymerase؛ Nirmatrelvir and ritonavir drug combination؛ GS-621763؛ Molnupiravir
سایر فایل های مرتبط با مقاله
مراجع
  1. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). Treasure Island (FL): StatPearls; 2022.
  2. Christie A, Mbaeyi SA, Walensky RP. CDC Interim Recommendations for Fully Vaccinated People: An Important First Step. JAMA. 2021;325:1501-2. doi: 10.1001/jama.2021.4367. PubMed PMID: 33688914.
  3. Delang L, Neyts J. Medical treatment options for COVID-19. Eur Heart J Acute Cardiovasc Care. 2020;9:209-14. doi: 10.1177/2048872620922790. PubMed PMID: 32363880; PubMed Central PMCID: PMCPMC7235633.
  4. Imran M, Kumar Arora M, Asdaq SMB, Khan SA, Alaqel SI, Alshammari MK, et al. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Molecules. 2021;26. doi: 10.3390/molecules26195795. PubMed PMID: 34641339; PubMed Central PMCID: PMCPMC8510125.
  5. Hashemian SMR, Pourhanifeh MH, Hamblin MR, Shahrzad MK, Mirzaei H. RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomed Pharmacother. 2022;146:112517. doi: 10.1016/j.biopha.2021.112517. PubMed PMID: 34902743; PubMed Central PMCID: PMCPMC8654603.
  6. Zhao J, Guo S, Yi D, Li Q, Ma L, Zhang Y, et al. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Res. 2021;190:105078. doi: 10.1016/j.antiviral.2021.105078. PubMed PMID: 33894278; PubMed Central PMCID: PMCPMC8059291.
  7. Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. Clin Infect Dis. 2023;76:165-71. doi: 10.1093/cid/ciac180. PubMed PMID: 35245942; PubMed Central PMCID: PMCPMC9383515.
  8. Kabinger F, Stiller C, Schmitzova J, Dienemann C, Kokic G, Hillen HS, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28:740-6. doi: 10.1038/s41594-021-00651-0. PubMed PMID: 34381216; PubMed Central PMCID: PMCPMC8437801.
  9. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386:509-20. doi: 10.1056/NEJMoa2116044. PubMed PMID: 34914868; PubMed Central PMCID: PMCPMC8693688.
  10. Wang Z, Yang L, Song XQ. Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. Front Immunol. 2022;13:1015355. doi: 10.3389/fimmu.2022.1015355. PubMed PMID: 36561747; PubMed Central PMCID: PMCPMC9763260.
  11. Xie Y, Yin W, Zhang Y, Shang W, Wang Z, Luan X, et al. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 2021;31:1212-4. doi: 10.1038/s41422-021-00570-1. PubMed PMID: 34584244; PubMed Central PMCID: PMCPMC8477624.
  12. Cox RM, Wolf JD, Lieber CM, Sourimant J, Lin MJ, Babusis D, et al. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. Nat Commun. 2021;12:6415. doi: 10.1038/s41467-021-26760-4. PubMed PMID: 34741049; PubMed Central PMCID: PMCPMC8571282.
  13. Schafer A, Martinez DR, Won JJ, Meganck RM, Moreira FR, Brown AJ, et al. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Sci Transl Med. 2022;14:3410. doi: 10.1126/scitranslmed.abm3410. PubMed PMID: 35315683; PubMed Central PMCID: PMCPMC8995034.
  14. Qian HJ, Wang Y, Zhang MQ, Xie YC, Wu QQ, Liang LY, et al. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Acta Pharmacol Sin. 2022;43:3130-8. doi: 10.1038/s41401-022-00895-6. PubMed PMID: 35296780; PubMed Central PMCID: PMCPMC8924727.
  15. Shen Y, Ai J, Lin N, Zhang H, Li Y, Wang H, et al. An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. Emerg Microbes Infect. 2022;11:1518-23. doi: 10.1080/22221751.2022.2078230. PubMed PMID: 35579892; PubMed Central PMCID: PMCPMC9176639.
  16. Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med. 2023;388:406-17. doi: 10.1056/NEJMoa2208822. PubMed PMID: 36577095; PubMed Central PMCID: PMCPMC9812289.
  17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. PubMed PMID: 33782057; PubMed Central PMCID: PMCPMC8005924.
  18. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6. doi: 10.1136/bmj.39489.470347.AD. PubMed PMID: 18436948; PubMed Central PMCID: PMCPMC2335261.
  19. Fischer WA, 2nd, Eron JJ, Jr., Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14:eabl7430. doi: 10.1126/scitranslmed.abl7430. PubMed PMID: 34941423; PubMed Central PMCID: PMCPMC10763622.
  20. Johnson MG, Strizki JM, Brown ML, Wan H, Shamsuddin HH, Ramgopal M, et al. Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. Infection. 2023;51:1273-84. doi: 10.1007/s15010-022-01959-9. PubMed PMID: 36648627; PubMed Central PMCID: PMCPMC9844162.
  21. Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T, Lyon R, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021;76:3286-95. doi: 10.1093/jac/dkab318. PubMed PMID: 34450619; PubMed Central PMCID: PMCPMC8598307.
  22. Khoo SH, FitzGerald R, Saunders G, Middleton C, Ahmad S, Edwards CJ, et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Infect Dis. 2023;23:183-95. doi: 10.1016/S1473-3099(22)00644-2. PubMed PMID: 36272432; PubMed Central PMCID: PMCPMC9662684
  23. Sinha S, N K, Suram VK, Chary SS, Naik S, Singh VB, et al. Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India. Cureus. 2022;14:e31508. doi: 10.7759/cureus.31508. PubMed PMID: 36532902; PubMed Central PMCID: PMCPMC9751243.
  24. Zou R, Peng L, Shu D, Zhao L, Lan J, Tan G, et al. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial. Front Pharmacol. 2022;13:939573. doi: 10.3389/fphar.2022.939573. PubMed PMID: 35784723; PubMed Central PMCID: PMCPMC9248931.
  25. Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281-93. doi: 10.1016/S0140-6736(22)02597-1. PubMed PMID: 36566761; PubMed Central PMCID: PMCPMC9779781
  26. Arribas JR, Bhagani S, Lobo SM, Khaertynova I, Mateu L, Fishchuk R, et al. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. NEJM Evid. 2022;1:EVIDoa2100044. doi: 10.1056/EVIDoa2100044. PubMed PMID: 38319178.
  27. Bruno G, Giotta M, Perelli S, De Vita G, Bartolomeo N, Buccoliero GB. Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19. Viruses. 2022;14. doi: 10.3390/v14112514. PubMed PMID: 36423123; PubMed Central PMCID: PMCPMC9695104.
  28. Bruno G, Perelli S, Giotta M, Bartolomeo N, De Vita G, Buccoliero GB. Efficacy and safety of oral antivirals in individuals aged 80 years or older with mild-to-moderate COVID-19: preliminary report from an Italian Prescriber Center. Infez Med. 2022;30:547-54. doi: 10.53854/liim-3004-9. PubMed PMID: 36482949; PubMed Central PMCID: PMCPMC9715007.
  29. Tiseo G, Barbieri C, Galfo V, Occhineri S, Matucci T, Almerigogna F, et al. Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience. Infect Dis Ther. 2023;12:257-71. doi: 10.1007/s40121-022-00729-2. PubMed PMID: 36441485; PubMed Central PMCID: PMCPMC9707131.
  30. Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis. Ann Med. 2022;54:516-23. doi: 10.1080/07853890.2022.2034936. PubMed PMID: 35118917; PubMed Central PMCID: PMCPMC8820829.
  31. Amani B, Zareei S, Amani B. Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19. Br J Clin Pharmacol. 2022;88:4403-11. doi: 10.1111/bcp.15449. PubMed PMID: 35762036; PubMed Central PMCID: PMCPMC9349444.
  32. Faust JS, Kumar A, Shah J, Khadke S, Dani SS, Ganatra S, et al. Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18-50 Years. Clin Infect Dis. 2023;77:1257-64. doi: 10.1093/cid/ciad400. PubMed PMID: 37387690.
  33. Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J Med Virol. 2023;95:e28441. doi: 10.1002/jmv.28441. PubMed PMID: 36576379; PubMed Central PMCID: PMCPMC9880713.
  34. Cheema HA, Jafar U, Sohail A, Shahid A, Sahra S, Ehsan M, et al. Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2023;95:e28471. doi: 10.1002/jmv.28471. PubMed PMID: 36606609.
  35. Zheng Q, Ma P, Wang M, Cheng Y, Zhou M, Ye L, et al. Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect. 2023;86:66-117. doi: 10.1016/j.jinf.2022.09.027. PubMed PMID: 36191676; PubMed Central PMCID: PMCPMC9523907.
آمار
تعداد مشاهده مقاله: 378
تعداد دریافت فایل اصل مقاله: 460


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب